This CABRI report, informed by data collected for CABRI’s COVID-19 Public Finance Response Monitor offers an overview of the landscape of COVID-19 vaccine financing and how procurement decisions are being made across the continent. It should aid practitioners and policymakers faced with the challenge of how to pay for, procure and distribute the COVID-19 vaccine, and facilitate cross-country learning amongst public financial management (PFM) and health practitioners. This information will be useful for the many African countries that have not yet begun, in earnest, country-owned or direct procurement of the COVID-19 vaccine and for those that will require many more doses than they have already secured. It should also contribute to improving cost-efficiency and effectiveness of future emergency vaccine programmes and the roll out of the COVID-19 vaccine in future years. Finally, it also aims to gently remind domestic actors of the importance of transparency and accountability and country ownership over vaccine programmes, both during normal times and times of crisis.